LSP closes largest ever European life sciences fund at $600 million
Category: Transactions Year: 2020
10 March 2020
LSP, the leading life sciences investor in Europe, is pleased to announce that it has held its final close of LSP 6 at the $600 million hard cap. This is the largest fund ever raised in Europe focused on life sciences ventures. Campbell Lutyens acted as global placement advisor.
LSP 6 will, like its predecessor funds, invest in 15-18, predominantly European private companies developing new medications or medical technologies, who turn cutting-edge scientific innovations into real-world healthcare solutions.
Due to strong investor demand LSP was able to raise $600 million, significantly more than the fund’s $450 million target. The success of the fundraise was mainly driven by LSP’s outstanding 32-year track record. In addition, investors recognized the potential of the large and fast-growing market opportunity in Europe for life sciences companies.